TheraDep Technologies

Executive Summary

TheraDep Technologies, headquartered in San Diego, is a privately held biotechnology company founded in 2018 that specializes in precision surface engineering for drug delivery and biomolecule immobilization. Its proprietary BioDep™ process leverages Cold Atmospheric Plasma (CAP) to create thin, uniform, covalently bonded bioactive coatings on various substrates, enhancing surface performance, biocompatibility, and localized drug delivery. The company targets medical device, pharmaceutical, and life sciences research markets, offering a versatile platform to improve device integration and therapeutic efficacy. Despite limited public financial data and an early-stage profile, the technology addresses a critical need in surface functionalization, potentially enabling sustained release and targeted therapy. TheraDep's approach differentiates through solvent-free, room-temperature deposition, preserving sensitive biomolecules. As a private entity with no disclosed funding rounds or revenue, the company's progression hinges on strategic collaborations and validation from industry partners. The executive summary highlights the core technology's promise while acknowledging the nascent commercial stage.

Upcoming Catalysts (preview)

• Q2 2026First Commercial Partnership with a Medical Device or Pharma Company40% success
• Q4 2026FDA 510(k) Clearance or Regulatory Milestone for a Device Coating30% success
• Q3 2026Publication of Peer-Reviewed Study Demonstrating In Vivo Efficacy of BioDep™ Coatings50% success